ESC launches new ACS, cardiac oncology registries

The European Society of Cardiology announced the launch of new registries on ACS and cardiac oncology, as part of the EURObservational Research Program.

The Cardiac Oncology Toxicity Registry will focus on drug-related cardiotoxicity for breast cancer treatments. During a 12-month pilot phase beginning in September, the registry will recruit 700 patients from cardiac imaging labs that perform cardiotoxicity assessment. Eligible patients will include those with breast cancer who are receiving or will receive chemotherapy and are being monitored for left ventricular function and drug-related toxicity; chemotherapy recipients with LV dysfunction and suspected, asymptomatic drug-related cardiotoxicity; and chemotherapy recipients with confirmed cardiotoxicity who are developing HF symptoms, according to a press release.

“Our goal is to collect information on current practices for identifying and treating [anti-breast-cancer drug-related cardiotoxicity],” registry chairperson Patrizio Lancelloti, MD, PhD, said in the release. “We will find out which patients are most at risk and how best to identify and manage this growing problem.”

Patrizio Lancelloti

The ACS Registry, also launching in September, will begin with a 6-month pilot phase across 10 to 12 countries, with a focus on STEMI.

“We will document adherence to ESC guidelines regarding interventions and drug treatments, and also record outcomes,” registry co-chairperson Uwe Zeymer, MD, said in the release. “Countries will then have evidence of the improvements needed in the acute care of STEMI patients, which they can show to politicians and health care providers.”

The ESC also announced initiation of the long-term phase of its Cardiomyopathies and Myocarditis Registry, which will include data on hypertrophic, dilated, restrictive and arrhythmogenic right ventricular cardiomyopathy, along with clinically suspected myocarditis. The registry is the first of its kind in Europe, and is intended to compare practices and guideline adherence related to cardiomyopathy and myocarditis throughout Europe, chairperson Perry Elliott, MD, said in the release.

“We want to know how patients are diagnosed, what their symptoms and outcomes are and how clinical practice varies between countries and centers,” Elliott said. “This registry will help raise the profile of a group of relatively uncommon or rare diseases so that we can develop new disease-specific therapies and ensure that all patients in Europe receive the same standard of care.”